secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2025-04-23T23:59:59+00:00
Accession:  0001104659-25-037746
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rezolute's Phase 3 sunRIZE study of ersodetug gets positive DMC recommendation; enrollment May, data Dec 2025
--------------------------------------------------------------------------------

- Independent DMC recommends continuation of sunRIZE study as planned; no need to increase sample size.
- Enrollment expected to complete in May 2025; topline data anticipated in December 2025.
- U.S. sites now activated and enrolling; global study across more than a dozen countries.
- Interim analysis evaluated primary endpoint of hypoglycemia events after ~50% of patients completed assessments.
- Rezolute remains blinded to interim data; DMC recommendation based on pre-specified futility and sample size assessment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465925037746/0001104659-25-037746-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465925037746/tm2512716d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-037746

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer